Investors Overview

    Press Release

    View printer-friendly version

    BD Unveils Next Generation Wireless Point-of-Care Diagnostic Device

    New BD Veritor™ Plus System Enables Fast and Accurate Test Results for Health Care Providers

    FRANKLIN LAKES, N.J., Sept. 21, 2016 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch of its next generation wireless rapid diagnostic system for detection of influenza A and B, respiratory syncytial virus (RSV) and group A strep, with new traceability and secure patient health record documentation features and functionality.

    The BD Veritor Plus is a next generation wireless rapid diagnostic system for detection of influenza A and B, respiratory syncytial virus (RSV) and group A strep, with new traceability and secure patient health record documentation features and functionality.

    The new wireless BD Veritor™ Plus System provides health care providers and laboratorians in physician offices, clinics, hospitals and integrated delivery networks (IDNs) with objective, lab-quality immunoassay test results within minutes. This rapid and accurate solution streamlines the point-of-care (POC) diagnostic workflow and enables providers to quickly review patient results to assist in determining the appropriate treatment in a single consultation. The system can help detect influenza A and B, respiratory syncytial virus (RSV) and group A strep while the patient is still on site, which enables faster decision making for an earlier intervention opportunity.

    The BD Veritor Plus System benefits from the demonstrated performance of the legacy BD Veritor System and offers new features to improve quality control (QC) by identifying QC results. The enhanced documentation functionality includes user ID, specimen ID and test kit lot to improve traceability, which decreases manual documentation.

    The new BD Veritor Plus System also offers the BD Cloud Connectivity Solution ― a technology that allows users to wirelessly transfer test data securely to an electronic medical record (EMR) or a laboratory information system (LIS) to enable data access across an entire IDN. This can help to reduce potential errors associated with manual documentation and streamlines POC testing workflow to enable physicians to more easily access test results  and use the information to determine next steps in patient care.

    Millions of people are sickened by influenza in the U.S. each year.i Additionally, most children will have respiratory syncytial virus (RSV) by the time they are twoii and 20 percent to 30 percent of sore throats in children are caused by group A Streptococcus.iii The BD Veritor Plus System, with enhanced features, can aid in the diagnosis of these disease states.

    "As we are on the cusp of the flu season, it is critical that providers have the diagnostic tools they need to assist them in quickly and accurately identifying infectious diseases, like flu, RSV and strep and in assigning treatment protocols," said Dave Hickey, president of Diagnostic Systems at BD. "The BD Veritor Plus System's ability to provide reliable test results and wirelessly transfer them to health records could ultimately lead to better outcomes through rapid detection and simplified workflow."

    For more information on the BD Veritor Plus System for use with CLIA-waived flu A+B, RSV and group A strep assays, please visit

    About BD
    BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and health care worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures, optimize respiratory care and support the management of diabetes. The company partners with organizations around the world to address some of the most challenging global health issues. BD has more than 45,000 associates across 50 countries who work in close collaboration with customers and partners to help enhance outcomes, lower health care delivery costs, increase efficiencies, improve health care safety and expand access to health. For more information on BD, please visit

    iCenters for Disease Control and Prevention. Seasonal Flu, More Information. Accessed August 15, 2016.  
    iiCenters for Disease Control and Prevention. Respiratory Syncytial Virus Infection (RSV): Infection and Incidence. Accessed August 19, 2016,  
    iiiCenters for Disease Control and Prevention. Get Smart: Know When Antibiotics Work. Sore Throat.‐patients/common‐illnesses/sore‐throat.html Accessed September 08, 2016.


    Troy Kirkpatrick                                                     Monique N. Dolecki
    BD Public Relations                                               BD Investor Relations
    858.617.2361                                                        201.847.5378                              

    Photo -

    To view the original version on PR Newswire, visit:

    SOURCE BD (Becton, Dickinson and Company)

    Investor Highlights


    Meet Jonathan

    Moments after crossing the finish line of a half marathon, Jonathan went into cardiac arrest due to a congenital defect in his artery.

    Drone Delivery Capabilities

    See how BD and WeRobotics worked to advance drones for healthcare in the Peruvian Amazon

    AMR Leadership

    BD solutions to combat antimicrobial resistance